Equities

Purple Biotech Ltd

Purple Biotech Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (ILa)15.50
  • Today's Change0.00 / 0.00%
  • Shares traded3.30k
  • 1 Year change-66.81%
  • Beta-0.2824
Data delayed at least 20 minutes, as of Jul 16 2024 08:19 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.

  • Revenue in ILS (TTM)0.00
  • Net income in ILS-67.90m
  • Incorporated1968
  • Employees20.00
  • Location
    Purple Biotech Ltd4 Oppenheimer St., Science ParkREHOVOT 7670104IsraelISR
  • Phone+972 39333121
  • Fax+972 35097196
  • Websitehttps://purple-biotech.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Merchavia Holdings and Investments Ltd460.00k-16.23m13.94m1.23k--0.4825--30.31-3.87-3.870.04091.720.0121--1.53374.59-42.78-3.37-43.98-3.46-----3,528.48-185.15---0.13460.00--90.08-10.25-349.99--37.97--
Nextage Therapeutics Ltd876.00k-4.07m21.29m--------24.31-0.1396-0.13960.03-0.09580.672--6.82---322.44-188.94---423.7625.6833.33-479.79-2,486.19---18.46------17.9927.21------
Kadimastem Ltd0.00-12.01m26.11m32.00---------1.22-1.220.00-1.040.00-------115.17-155.33-1,153.60-1,831.12-----------9.443.22------47.14---50.73--
Purple Biotech Ltd0.00-67.90m47.78m20.00--0.3811-----0.2679-0.26790.000.40860.00----0.00-40.57-37.24-47.99-41.28-------9,415.70----0.0098------8.25---28.45--
X T L Biopharmaceuticals Ltd1.64m-81.38m48.73m33.00--0.599--29.66-0.3695-0.36950.00750.14930.0192--0.701249,784.54-94.96-53.17-111.98-59.10---2.33-4,953.75-1,084.42----0.00---85.80---7.97---53.12--
Matricelf Ltd0.00-13.83m57.22m----2.12-----0.8777-0.87770.001.670.00-------39.69---42.80--------------0.0527-------10.77------
DNA Group TR Ltd306.00k-1.18m87.20m14.00--1.10--284.97-0.0088-0.00880.00250.64290.0038--1.3721,857.14-1.45-23.54-1.46-26.27-----384.64-7,406.24----0.00---45.36--95.00------
Bonus Biogroup Ltd0.00-28.84m178.69m58.00--8.13-----0.0675-0.06750.000.01880.00----0.00-54.73-76.10-63.36-97.19------------0.331------26.29--19.30--
BioLine RX Ltd42.18m-177.85m208.43m79.00--4.00--4.94-0.184-0.1840.0420.04350.1939--6.40533,872.80-81.75-52.74-127.94-65.4355.84---421.69-3,501.791.05-519.430.4642-------142.93---50.72--
Data as of Jul 16 2024. Currency figures normalised to Purple Biotech Ltd's reporting currency: Israeli Shekel ILS

Institutional shareholders

0.57%Per cent of shares held by top holders
HolderShares% Held
KSM Mutual Funds Ltd.as of 30 Apr 2024768.19k0.28%
Meitav Mutual Funds Ltd.as of 30 Apr 2024496.36k0.18%
Migdal Mutual Funds Ltd.as of 30 Apr 2024232.12k0.08%
Psagot Mutual Funds Ltd.as of 30 Apr 202446.93k0.02%
Harel Mutual Funds Ltd.as of 30 Apr 202415.79k0.01%
More ▼
Data from 31 Mar 2024 - 30 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.